Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06670170 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06670170 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT06670170, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.
Interventions
- DRUG PF-07976016 Formulation A
- DRUG PF-07976016 Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06670170
The ClinicalTrials.gov registry entry for NCT06670170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-07976016 Formulation A is the first listed.
NCT06670170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06670170 about?
NCT06670170 is a clinical study titled "A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults". The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.
What is the current status of trial NCT06670170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-11-05. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT06670170?
The interventions under investigation include: PF-07976016 Formulation A (DRUG), PF-07976016 Formulation B (DRUG).
Who is sponsoring clinical trial NCT06670170?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.